Event Date/Time: Nov 11, 2004
End Date/Time: Nov 12, 2004
The true test of validation comes only when a selective inhibitor for the chosen target is advanced to the clinic and shown to be efficacious in the appropriate human disease. However, advancing the wrong target to this stage is a costly mistake. Early validation and invalidation approaches continue to improve to allow researchers to make the most informed choice early and advance that chosen target toward the clinic for final evaluation. In vivo validation using RNAi, imaging and other techniques will receive focused attention at this meeting along with an in-depth analysis of the target validation decision process. Ample time for networking and facilitated discussion with conference participants from biotech and the pharmaceutical industry will be a signature feature of this event. Attend to learn more.